Botrezomib is an anti-cancer drug (antineoplastic agent) and the first therapeutic Proteosome Inhibitor (PI) marketed for this purpose and is approved worldwide, including in the U.S. and Europe, for treating untreated or relapsed multiple myeloma and mantle cell lymphoma. Complete remission (CR) or very good partial remission (VGPR) has been observed in multiple myeloma (MM) therapy following the clinical use of this drug.
Chemically, Bortezomib is a dipeptidyl boronic acid that binds reversibly to CT-L subunit of the proteasome. It has also been reported to bind to C-L and T-L subunits with lower affinity. Although bortezomib is a reversible inhibitor, the boronate-proteasome complex has a low degree of dissociation and remains stable for several hours
Storage conditions: Store in a refrigerator in a well-closed container and protected from light.
Packaging: light resistant glass vial